PT -期刊文章盟Jorge Patino Murillas盟萨姆-扎Zadegan盟纳塔莉亚•罗查AU -尼古拉斯Karagas盟将一盟-布列塔尼邓肯盟艾琳Furr-Stimming TI -褪黑素亨廷顿病(HD)基因携带者HD-Related睡眠障碍——一个试点研究(p1 - 11.013) - 10.1212 / WNL援助。0000000000203180 DP - 2023年4月25日TA -神经病首页学第六PG - 3313 - 100 IP - 17补充2 4099 - //www.ez-admanager.com/content/100/17_Supplement_2/3313.short 4100 - //www.ez-admanager.com/content/100/17_Supplement_2/3313.full所以Neurology2023 4月25日;100 AB -目的:评价外源性褪黑素在改善睡眠质量的功效在亨廷顿病(HD)基因携带者。背景:各种睡眠障碍已确定在高清。褪黑激素水平低可能解释扰乱生理行为高清[1]。有证据表明睡眠质量改善测量的匹兹堡睡眠质量指数(PSQI)个人接收褪黑激素[2]。这是第一个研究评估在高清褪黑素的功效。设计/方法:随机、双盲,安慰剂对照,交叉,概念验证研究。高清基因携带者与PSQI≥5和稳定的药物在过去的2个月从UTHealth招募,休斯顿HDSA卓越中心。高清睡眠问卷,PSQI埃普沃思嗜睡量表(ESS)、医院焦虑和抑郁量表(已经),临床全球印象(CGI)规模,UHDRSc接种。Wilcoxon符号秩检验是用来分析数据。结果:我们招收15例(平均年龄47.5岁,46%女性),73%的白人,13%的非裔美国人,13%是西班牙人。 As expected, both melatonin and placebo groups showed significant differences in the PSQI-6 since they were taking medications for sleep. Interestingly, compared to baseline the melatonin group had significantly improved scores in the HD Sleep Questionnaire, and increased scores in the improvement component of the CGI. No differences were noted in the HADS or ESS.Conclusions: This pilot study in HD gene carriers demonstrates a potential benefit of melatonin for sleep disturbances. Consistent with previous data in other neurodegenerative diseases, melatonin can positively impact sleep quality. Analysis of other variables including changes in BMI, subcomponents of the UHDRS, and measures of quality of life will be forthcoming. Future studies that use objective assessments such as polysomnogram or actigraphy, a larger sample size, and differentiating between disease stages might provide valuable information regarding the utility of melatonin in HD.Disclosure: Dr. Patino Murillas has nothing to disclose. Dr. Zadegan has nothing to disclose. Natalia Pessoa Rocha has nothing to disclose. An immediate family member of Dr. Karagas has received personal compensation for serving as an employee of Thirty Madison. An immediate family member of Dr. Karagas has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Thirty Madison. An immediate family member of Dr. Karagas has stock in Thirty Madison. Mr. Tanigaki has nothing to disclose. Mrs. Duncan has nothing to disclose. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva Pharmaceuticals. The institution of Dr. Furr-Stimming has received research support from Cures within Reach. The institution of Dr. Furr-Stimming has received research support from Huntington’s Disease Society of America. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care.